Borrelia antigens

US8129165B2 · kind B2 · utility

Assignee

• Intercell AG · AT

Inventors

• Urban Lundberg · Wien, AT
• Andreas Meinke · Pressbaum, AT
• Eszter Nagy · Wien, AT
• Alexander Von Gabain · Wien, AT
• Birgit Noiges · Wien, AT
• Dieter Gelbmann · Weiden am See, AT
• Albina Poljak · Wien, AT
• Christine Triska · Wien, AT

Key dates

• Filing date: Sep 14, 2007
• Grant date: Mar 6, 2012
• Expiry date: Sep 14, 2027

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to isolated nucleic acid molecules which encode a protein, isolated nucleic acid molecules which encode a hyperimmune serum reactive antigen, a vector which comprises such nucleic acid molecule, a host cell comprising such vector, a hyperimmune reactive antigen from Borrelia species, proteins which are preferably hyperimmune serum reactive antigens, hyperimmune serum reactive antigens, antigens, a process for producing such proteins, hyperimmune serum reactive antigens or antigens, a process for producing a cell which expresses such protein, hyperimmune serum reactive antigen or antigen, an antibody binding to such protein, hyperimmune serum reactive antigen or antigen, a hybridoma cell producing such antibody, methods for producing such antibody, a pharmaceutical composition comprising such nucleic acid molecule, protein, hyperimmune serum reactive antigen, antigen or antibody, the use of such nucleic acid molecule, protein, hyperimmune serum reactive antigen, antigen or antibody for the manufacture of a medicament, methods for identifying an antagonist capable of reducing or inhibiting the interaction activity of such protein, hyperimmune serum react…